EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intranasal irbesartan reverts cognitive decline and activates the PI3K/AKT pathway in an LPS-induced neuroinflammation mice model

Filipa Gouveia, Carla Fonseca, Ana Silva, Antoni Camins, M Teresa Cruz, Miren Ettcheto, Ana Fortuna

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2023.111471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Filipa Gouveia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal; Coimbra Institute for Biomedical Imaging and Translational…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Generalitat de Catalunya, Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: New strategies are urgently needed to manage and delay the development of Alzheimer's disease (AD). Neuroinflammation is a significant contributor to cognitive decline in neurodegenerative diseases, including AD. Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) protect hypertensive patients against AD, but the cellular and molecular mechanisms underlying these effects remain unknown. In light of this, the protective effects of three ARBs and three ACEIs against neuroinflammation and cognitive decline were investigated through comprehensive pharmacologicalin vitro/in vivoscreening. METHODS: BV-2 microglia cells were exposed tolipopolysaccharide (LPS) and treated with ARBs and ACEIs to provide initial insights into the anti-inflammatory properties of the drugs. Subsequently, irbesartan was selected, and its efficacy was evaluated inC57/BL6 male miceintranasally administered with irbesartan and injected with LPS. Long-term memory and depressive-like behavior were evaluated; dendritic spines were measured as well as neuroinflammation, neurodegeneration and cognitive decline biomarkers. RESULTS: Irbesartan mitigated memory loss and depressive-like behavior in mice treated with LPS, probably because itincreased spine density, ameliorated synapsis dysfunction and activated the PI3K/AKT pathway. Irbesartan elevated the levels of hippocampalsuperoxide dismutase2 andglutathione peroxidaseandsuppressed LPS-induced astrogliosis. CONCLUSIONS: Overall, this study provides compelling evidence that multiple intranasal administrations of irbesartan can effectively prevent LPS-induced cognitive decline by activating pathways involved in neuroprotection and anti-inflammatory events. These findings underscore the potential of irbesartan as a preventive strategy against the development of AD and other neurodegenerative conditions associated with neuroinflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansMaleMiceAnimalsIrbesartanAngiotensin-Converting Enzyme InhibitorsProto-Oncogene Proteins c-aktLipopolysaccharidesPhosphatidylinositol 3-KinasesNeuroinflammatory DiseasesAngiotensin Receptor AntagonistsAdministration, IntranasalAnti-Inflammatory Agents

Stichwörter der Autor:innen

Alzheimer’s diseaseIntranasalIrbesartanNeuroinflammationRenin angiotensin system

Substanzen

IrbesartanAngiotensin-Converting Enzyme InhibitorsProto-Oncogene Proteins c-aktLipopolysaccharidesPhosphatidylinositol 3-KinasesAngiotensin Receptor AntagonistsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal; Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute of Nuclear Sciences Applied to Health (IC…
  • CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; CIBB-Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.
  • Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, Universitat de Barcelona, Barcelona, Spain; Institute of Neurosciences, Universitat de Barcelona, Barcelona, Spain;…
  • Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal; CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; CIBB-Center for Innovative Biomedicine…

Förderung

  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
  • Generalitat de Catalunya
  • Fundação para a Ciência e a Tecnologia
  • Ministerio de Ciencia e Innovación

Zitieren

APA

Gouveia, F., Fonseca, C., Silva, A., Camins, A., Teresa Cruz, M., Ettcheto, M., & Fortuna, A. (2024). Intranasal irbesartan reverts cognitive decline and activates the PI3K/AKT pathway in an LPS-induced neuroinflammation mice model. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111471

Vancouver

Gouveia F, Fonseca C, Silva A, Camins A, Teresa Cruz M, Ettcheto M, et al. Intranasal irbesartan reverts cognitive decline and activates the PI3K/AKT pathway in an LPS-induced neuroinflammation mice model. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2023.111471

BibTeX
@article{Gouveia2024,
  author = {Gouveia, Filipa and Fonseca, Carla and Silva, Ana and Camins, Antoni and Teresa Cruz, M and Ettcheto, Miren and Fortuna, Ana},
  title = {Intranasal irbesartan reverts cognitive decline and activates the PI3K/AKT pathway in an LPS-induced neuroinflammation mice model},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2023.111471}
}
Kostenlos starten →